Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03731819
Other study ID # SNUH-2018-1276
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 5, 2018
Est. completion date May 4, 2022

Study information

Verified date May 2022
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to establish abbreviated PB MRI protocol for patients on regular imaging follow-up for pancreas cystic neoplasm.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 4, 2022
Est. primary completion date November 12, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - on follow-up for pancreas intraductal mucinous neoplasm - OR incidentally detected pancreas cyst (equal to or larger than 1cm) - AND scheduled for CECT or has CECT within a months - AND sign informed consent Exclusion Criteria: - Any absolute or relative contra-indication for contrast-enhanced MRI - No pancreas cystic neoplasm - History of pancreatectomy - History of any procedure for pancreatic cyst (ablation, aspiration...) in a year - Hemosiderosis - Suspicion of acute pancreatitis

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Abbreviated PB MRI
Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Table time of Abbreviated PB MRI total scan time 1 day after PB MRI acquisition
Secondary In room time of Abbreviated PB MRI time spent in room by participants (difference between walk-in and walk-out times) 1 day after PB MRI acquisition
Secondary Diagnostic confidence subjective diagnostic confidence for pancreas cystic neoplasm on five point scale 6 months after participants enrollment
Secondary Image quality overall image quality of Abbreviated PB MRI 6 months after participants enrollment
Secondary Requirement for re-examination clinical need for re-examination due to suboptimal image quality 6 months after participants enrollment
See also
  Status Clinical Trial Phase
Recruiting NCT04970056 - Pancreatic Cancer Early Detection Consortium
Recruiting NCT05155878 - Prognostic Factors in Periampullary Tumors and Cysts
Recruiting NCT03536793 - Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
Completed NCT06227871 - A Retrospective Analysis of Pancreatic Injuries and Treatment Outcomes
Recruiting NCT03855800 - Molecular Detection of Advanced Neoplasia in Pancreatic Cysts N/A
Recruiting NCT05714111 - Radiology Registry on Pancreatic Malignancies
Recruiting NCT04104230 - Quebec Pancreas Cancer Study
Recruiting NCT03568630 - Blood Markers of Early Pancreas Cancer
Active, not recruiting NCT04200131 - Moray Micro Forceps and Pancreatic Cyst N/A
Active, not recruiting NCT03305146 - Feasibility of Molecular Biology in Pancreatic Cyst Tumors N/A
Completed NCT03820531 - DNA-mutation Analysis in Cyst Fluid of Suspected Intraductal Papillary Mucinous Neoplasia of the Pancreas N/A
Recruiting NCT06055010 - Improving Pancreatic Cancer Care by the Use of Computational Science and Technology
Recruiting NCT04324294 - Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions Phase 1
Completed NCT03172572 - A Pan-European Study on Minimally Invasive Versus Open Pancreatoduodenectomy in High-volume Centers
Completed NCT01807325 - RNA Sequencing of Solid and Cystic Lesions of the Pancreas
Completed NCT04064034 - ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer N/A